Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 2375 • ACR Convergence 2023
Clinical Characteristics of ANCA-associated Vasculitis with High Levels of Serum Interleukin 7
Shoichi Fukui¹, Haruna Matsuo², Kanako Kojima³, Shota Kurushima¹, Tohru Michitsuji⁴, Yoshika Tsuji⁵, Toshimasa Shimizu³, Masataka Umeda³, Remi Sumiyoshi⁵, Takashi Igawa¹, Tomohiro Koga⁵, Shin-ya Kawashiri¹, Naoki Iwamoto¹, Tomoki Origuchi¹ and Atsushi Kawakami¹, ¹Nagasaki University, Nagasaki, Japan, ²Nagasaki University, Nagasaki City, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Medical Sciences, Nagasaki, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan
Background/Purpose: Interleukin 7 (IL-7) is a hematopoietic growth factor produced by stromal cells in the bone marrow and thymus, which is indispensable in maintaining immune…
Abstract Number: 2496 • ACR Convergence 2023
HXB-319, a New Generation Mesenchymal Stromal Cell (MSC) Therapy, Alleviates Neutrophilic Inflammation, and End-organ Damage in Pulmonary Renal Syndromes by Inducing FoxP3+ Tregs, and by Promoting TNFα-stimulated gene-6 (TSG-6) over Expression
Hulya Bukulmez¹, Adrienne Dennis¹, Jane Reese-Koc², Scott Sieg² and Steven Emancipator², ¹MetroHealth Medical Center, Department of Pediatrics, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH
Background/Purpose: Mesenchymal stromal cells (MSCs) have been shown to be safe therapies in more than 100 human clinical trials. However, MSCs clinical efficacy is variable,…
Abstract Number: 0687 • ACR Convergence 2023
Avacopan for the Treatment of ANCA-associated Vasculitis. Real World Experience in Spain
Georgina Espigol-Frigole¹, Maria C Cid², Juliana Bordignon Draibe³, Maria Carmen Prados⁴, Elena Guillen⁵, Ana Huerta⁶, Javier Villacorta⁷, Cristina Vega⁸, Judith Martins⁹, Borja Gracia¹⁰ and Enrique Morales¹¹, ¹Autoimmune Diseases. Hospital Clinic Barcelona, Barcelona, Spain, ²Hospital Clinic Barcelona, Barcelona, Spain, ³Hospital Bellvitge, Barcelona, Spain, ⁴Hospital Torrecárdenas, Almeria, Spain, ⁵Hospital Clínic de Barcelona, Barcelona, Spain, ⁶Hospital Puerta de Hierro, Madrid, Spain, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital La Paz, Madrid, Spain, ⁹Hospital de Getafe, Madrid, Spain, ¹⁰Hospital Lozano Blesa, Zaragoza, Spain, ¹¹Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: ANCA-associated vasculitis are chronic and relapsing diseases. Relapses are frequently associated with organ damage accrual as a consequence of disease activity or treatment-related side…
Abstract Number: 1538 • ACR Convergence 2023
Large Vessel Involvement in Antineutrophil Cytoplasmic Antibody- Associated Vasculitis: A Single Center Experience over Two Decades
Mahmut Kaymakci¹, Mohanad Elfishawi¹, Hannah Langenfeld², Andrew Hanson², Cynthia Crowson¹, Melanie Bois¹, Umar Ghaffar¹, Ulrich Specks¹, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is currently categorized under the small vessel vasculitides and includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA),…
Abstract Number: 2376 • ACR Convergence 2023
Eosinophil Activation as a Biomarker for Discriminating Active and Remission Phase in ANCA-Associated Vasculitis
Teppei Hashimoto¹, Kazuteru Noguchi², Yuko Minagawa², Takeo Abe², Masao Tamura², Tetsuya Furukawa¹, Naoto Azuma² and Kiyoshi Matsui¹, ¹Hyogo Medical University, Nishinomiya, Japan, ²Hyogo Medical University, School of Medicine, Nishinomiya, Japan
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening disease requiring complex management due to a lack of suitable biomarkers. Elevated or persistently positive…
Abstract Number: 0007 • ACR Convergence 2023
Targeting NF-κB Signalling in B Cells from ANCA-associated Vasculitis Impairs B Cell Biology as a Potential Novel Target
Ana Merino-Vico¹, Jan Piet van Hamburg¹, Paul Tuijnenburg¹, Aram Al-Soudi¹, Carlo Bonasia², Boy Helder¹, Abraham Rutgers², Wayel H. Abdulahad², Coen A. Stegeman², Jan-Stephan Sanders², Laura Bergamaschi³, Paul A. Lyons³, Theo Bijma², Laura Van Keep¹, Kirsten wesenhagen¹, Aldo Jongejan¹, Henric Olsson⁴, Niek De Vries¹, Taco W. Kuijpers¹, Peter Heeringa² and Sander Tas⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³University of Cambridge, Cambridge, United Kingdom, ⁴AstraZeneca, Gothenburg, Sweden, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: B cells have gained increased interest in ANCA-associated vasculitis (AAV) research, as the treatment of this autoimmune disease with rituximab (an anti-CD20 B cell…
Abstract Number: 0688 • ACR Convergence 2023
Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP)
Federico Alberici¹, Carlo Salvarani², Christine Chan³, Achim Obergfell⁴ and Tamara Popov⁴, ¹Universita degli Studi di Brescia, Brescia, Italy, ²Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³CSL Vifor, Redwood City, CA, ⁴CSL Vifor, Glattbrugg, Switzerland
Background/Purpose: Avacopan, a selective C5aR1 inhibitor, has demonstrated efficacy and safety over 52 weeks in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. However, efficacy and…
Abstract Number: 1539 • ACR Convergence 2023
Digital Ischemia, a Rare Manifestation in Anti-neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV)
Adil Vural¹, Chao Zhang² and Kinanah Yaseen¹, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Digital ischemia is a rare, yet severe manifestation observed in AAV. Despite gangrene being a major criterion in the Birmingham Vasculitis Activity Score, this…
Abstract Number: 2377 • ACR Convergence 2023
The Impact of Chronologic versus Biologic Age on the Risk of Severe Infection, End-Stage Renal Disease, and Death in Older Adults with ANCA-Associated Vasculitis
Sebastian Sattui¹, Xiaoqing Fu², Claire Cook², Shruthi Srivatsan², Yuqing Zhang² and Zachary Wallace³, ¹University of Pittsburgh, Pittsburgh, PA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Older adults with ANCA-associated vasculitis (AAV) have distinct clinical presentations and outcomes when compared to younger adults. Despite a high incidence of AAV in…
Abstract Number: 0217 • ACR Convergence 2023
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Tali Eviatar¹, Victoria Furer², Ilana Kaufman³, David levartovsky², Ofir Elalouf², Devy Zisman⁴, Tal Gazitt⁵, Amir Haddad⁴, Muna Elias⁶, Joy Feld⁷, Alexandra Balbir-Gurman⁸, Yolanda Braun Moscovici⁹, Sara Pel¹⁰, sharon Nevo¹¹, Daphna Paran² and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Ramat Gan, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Tel Aviv Medical Center, Petah-Tikva, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶rheumatology unit, Haifa, Israel, ⁷Carmel and Zvulun Medical Centre, Haifa, Israel, ⁸Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁹Rambam Heath Care Campus, Haifa, Israel, ¹⁰Tel Aviv Medical Center, Modiin, Israel, ¹¹Tel Aviv Sourasky Medical Center, Givataim, Israel
Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
Abstract Number: 0689 • ACR Convergence 2023
Use of Avacopan in Patients with ANCA-associated Vasculitis and Estimated Glomerular Filtration Rate < 15 mL/min/1.73m2
Bryce Barr, Kim Cheema, Aurore Fifi-Mah, Stephanie Garner, Louis Girard and Jeffrey Ma, University of Calgary, Calgary, AB, Canada
Background/Purpose: Glomerulonephritis represents a severe manifestation of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) and is associated with substantial morbidity and mortality. Therefore, maximal recovery…
Abstract Number: 1540 • ACR Convergence 2023
Evaluation of the Validity of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Antineutrophil Cytoplasmic Antibody-associated Vasculitis for an Asian Population on the Basis of the Patterns of Organ Involvement
Ryo Kuwata¹, Yuko Shirota², Tsuyoshi Shirai³, Hiroyuki Yamashita¹, HIroko Sato³, Yumiko Oka², Takao Kodera², Kyoko Motomura¹, Hiroshi Kaneko⁴, Junichi Kameoka², Hiroshi Fujii³ and Tomonori Ishii⁵, ¹Department of Rheumatology, National Center for Global Health and Medicine, Tokyo, Japan, ²Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, ³Department of Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁴Division of Rheumatic Disease, National Center for Global Health and Medicine, Tokyo, Japan, ⁵Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: The European Medicines Agency (EMA) algorithm has been widely accepted as a conventional and reliable method to diagnose ANCA-associated vasculitis (AAV). In 2022 the…
Abstract Number: 2378 • ACR Convergence 2023
Longitudinal Trajectories of Renal Function in ANCA-Associated Vasculitis: Findings from the Expanded Mass General Brigham Cohort
Jennifer Hanberg¹, Claire Cook¹, Xiaoqing Fu¹, Hyon K. Choi², Yuqing Zhang³ and Zachary Wallace⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA
Background/Purpose: ANCA-associated vasculitis (AAV) commonly causes renal damage, leading to a spectrum of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Quantitative descriptions of…
Abstract Number: 0291 • ACR Convergence 2023
Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics
Shun Nomura, Yasuhiro Shimojima, Takanori Ichikawa, Daigo Miyazaki, Dai Kishida and Yoshiki Sekijima, Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan
Background/Purpose: Muscular involvement develops as the initial manifestation of small-sized vessel vasculitis (SV) and medium-sized vessel vasculitis (MV).The musculoskeletal lesion has been found as a…
Abstract Number: 0690 • ACR Convergence 2023
Treating Patients with ANCA-Associated Vasculitis and Very Severe Renal Injury with an Intensified B Cell Depletion Therapy: Comparison with a Control Cohort Receiving a Conventional Therapy
Dario Roccatello¹, Savino Sciascia², SILVIA GRAZIETTA FODDAI³, gIACOMO QUATTROCCHIO⁴, MASSIMO RADIN³, IRENE CECCHI³, ALICE BARINOTTI³, ELENA RUBINI³, MICHELA FERRO⁴, EMANUELE DE SIMONE⁴, carla naretto⁴, ANTONELLA BARRECA⁵, ANDREA SAMMARTINO⁴, DANIELA ROSSI⁴ and ROBERTA FENOGLIO⁴, ¹University of Torino, Torino, Italy, ²University of Turin, Torino, Italy, ³University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, ⁴University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Turin, Italy, ⁵Pathology Unit, Città della Salute e della Scienza, Turin, Italy
Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitides associated with antineutrophil cytoplasm antibodies (AAV) in…

« Previous Page
1
…
5
6
7
8
9
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].